Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

NCT00232271 is registered in ClinicalTrials.gov with Melbourne Health as lead sponsor.

NCT NCT00232271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00232271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.
Lead sponsor
Melbourne Health
Phase
Phase 4
Overall status
Terminated
Start date
August 31, 2005
Completion date
February 28, 2011
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

deep vein thrombosis